NTLA-2002 – Talk Bio

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study

6 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Functional, Gene Modification, Intellia, NTLA-2002, Phase 2 Clinical Trials, Swelling attacks

CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure

Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy

11 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, NTLA-2002, single-dose

Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data